Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
about
Role of cytochrome P450 in drug interactionsRisk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and societyPharmacogenetics and pharmacogenomicsMolecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugsImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsPharmacogenomics: the promise of personalized medicineMolecular genetics of the human cytochrome P450 monooxygenase superfamilyThe effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomesDisposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphismGenetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity.Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system.Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugsThe association of CYP2D6 genotype and postoperative nausea and vomiting in orthopedic trauma patientsClinically significant pharmacokinetic drug interactions between antiepileptic drugs.The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.Ethnic differences in drug metabolism.Pharmacogenomics: a systems approach.Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trialsPolymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Frequency of human CYP2D6 mutant alleles in a normal Chinese population.An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotypeThe pharmacogenetics of analgesia: toward a genetically-based approach to pain management.Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel studyGenetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.Variability in the elimination of mianserin in elderly patients.Mephenytoin and sparteine oxidation: genetic polymorphisms in DenmarkCodeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.Evidence for the polymorphic oxidation of debrisoquine in the Thai population.Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjectsPerturbation of paracetamol urinary metabolic ratios by urine flow rate.Evidence for polymorphic oxidation of sparteine in Japanese subjectsDebrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.Sparteine oxidation polymorphism: a family study.
P2860
Q21245066-C5EAF3B7-2C7E-43CD-9C9C-16987AE6A892Q24289220-62E584DA-100F-419A-A80D-10A04ED98CACQ24564983-5CBE4A93-8F09-4DFD-860E-A3F0BFC0A404Q24683013-F88F7059-8F8A-4DD3-A2E1-7002E8AE562DQ26787099-01062FB4-BDB7-4204-A5C1-AD98E4730769Q28210286-B2932385-427A-403A-9A8F-AAD9CB3099D4Q28293994-270E04F6-ACF0-4551-8A2D-840297334CD0Q28378938-0746EDDB-1DAE-4024-AE26-F760E174B25AQ28609390-8957241B-ABC4-410B-B9FD-1BE593454A69Q31144283-95906013-EFCF-42AA-95FA-0C0521B34D7EQ33245041-A2C3E26F-0EC2-42A3-A008-89A95F0DB226Q33538523-96DB5B8C-0C9A-4673-A17C-22E0A0C8A791Q33630990-7ED62AED-49DA-4607-A8A3-78C853FB9C1CQ33632924-8F16F655-B24D-4995-9748-9BC22052A3D6Q33641660-D07B2419-37EF-4E0E-9E48-8F50BE73F38DQ33668831-445E9E38-A28A-48E2-BF4B-92C52A852C95Q33670797-F90BE15B-802F-4CA1-A667-3BD6460A95A1Q33899650-2EB7C7E9-3001-431A-A619-89C492715B71Q34093123-4285E4DE-3499-402F-BD04-F71313350C53Q34137575-FF1283E1-516F-47B4-95C2-2848F7AD1CF9Q34180464-A2A9615F-30A5-4A99-9125-AEF573A8670FQ34331552-4DCCB98B-D730-44C3-AFF9-7E79021CE32BQ34346439-15904BFF-6B19-4992-9CF6-D980FA6E8382Q34347560-EF1CFCD0-3B09-4B64-A624-76D058286094Q34355220-F4FF6CDB-A81D-48D6-835C-AB798957E62FQ34358272-FCA7B103-19DE-4145-8312-FB7976B9A5B2Q34358893-165FE4AD-9EF3-42BD-90A0-BC71D5728E13Q34397040-CF52E39A-F1BB-4261-9B45-085E4AA8DD9FQ34397048-4B30F8B1-8C16-4FC1-ACAF-4464D62676F6Q34397680-6216AF81-8F9C-4B4F-8B28-B54351A8D8B3Q34398035-BD7950F2-4464-4524-9AE9-14DC3176EA0FQ34398153-887C1C35-639F-49F7-9C20-005E9178C099Q34398228-1F44DC1D-EF43-4D63-8AE9-FED241A4CE21Q34398234-179AFD8B-5C82-44ED-ADAC-4D4671F9BC4EQ34398346-929C7817-7565-4065-A0CD-36CA65837995Q34398477-C7CF50FC-D6FE-44D0-BF41-AEBE71557804Q34403268-3BCD7E1E-1EDE-4ACE-837E-EDC634A904F3Q34416359-947112F6-FA0D-43FB-945A-0622833D151BQ34418240-63BBB700-A5CB-44A5-86DB-14DEF0804027Q34447491-EB9842BC-7E24-40EC-9346-EDC3644BA146
P2860
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
description
1979 nî lūn-bûn
@nan
1979 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1979 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
name
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@ast
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@en
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@nl
type
label
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@ast
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@en
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@nl
prefLabel
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@ast
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@en
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@nl
P2093
P356
P1476
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
@en
P2093
B Steincke
H J Dengler
M Eichelbaum
N Spannbrucker
P2888
P304
P356
10.1007/BF00562059
P577
1979-09-01T00:00:00Z
P6179
1042177911